Ameritas Investment Partners Inc. Invests $200,000 in QuidelOrtho Corporation $QDEL

Ameritas Investment Partners Inc. bought a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 6,923 shares of the company’s stock, valued at approximately $200,000.

Other institutional investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of QuidelOrtho by 11.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,773 shares of the company’s stock valued at $587,000 after purchasing an additional 1,721 shares in the last quarter. Phocas Financial Corp. boosted its holdings in shares of QuidelOrtho by 46.2% during the 1st quarter. Phocas Financial Corp. now owns 114,223 shares of the company’s stock worth $3,994,000 after buying an additional 36,091 shares in the last quarter. New Age Alpha Advisors LLC acquired a new stake in shares of QuidelOrtho during the 1st quarter worth approximately $332,000. Deutsche Bank AG increased its stake in shares of QuidelOrtho by 215.2% in the 1st quarter. Deutsche Bank AG now owns 358,889 shares of the company’s stock valued at $12,550,000 after acquiring an additional 245,033 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in QuidelOrtho by 10.6% in the first quarter. Invesco Ltd. now owns 3,813,833 shares of the company’s stock worth $133,370,000 after purchasing an additional 366,387 shares during the period. Institutional investors own 99.00% of the company’s stock.

Analyst Ratings Changes

QDEL has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their target price on QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a research report on Friday, November 7th. Citigroup reissued a “neutral” rating and issued a $33.00 price target (down previously from $40.00) on shares of QuidelOrtho in a research report on Tuesday, October 7th. Zacks Research downgraded shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Finally, UBS Group lifted their price objective on shares of QuidelOrtho from $26.00 to $31.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, QuidelOrtho has an average rating of “Reduce” and an average target price of $38.20.

QuidelOrtho Trading Down 0.5%

Shares of QDEL stock opened at $27.36 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 1.12. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -4.18 and a beta of 0.35. QuidelOrtho Corporation has a 52-week low of $19.50 and a 52-week high of $49.45. The company has a 50-day simple moving average of $26.62 and a two-hundred day simple moving average of $27.70.

QuidelOrtho (NASDAQ:QDEL) last posted its earnings results on Wednesday, November 5th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.51 by $0.29. The firm had revenue of $699.90 million for the quarter, compared to analysts’ expectations of $667.45 million. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. The company’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.85 EPS. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. Research analysts anticipate that QuidelOrtho Corporation will post 2.3 EPS for the current fiscal year.

Insider Buying and Selling at QuidelOrtho

In other QuidelOrtho news, CFO Joseph M. Busky acquired 4,770 shares of QuidelOrtho stock in a transaction on Monday, November 24th. The stock was purchased at an average price of $26.06 per share, for a total transaction of $124,306.20. Following the purchase, the chief financial officer directly owned 6,920 shares of the company’s stock, valued at $180,335.20. This trade represents a 221.86% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Brian J. Blaser bought 23,500 shares of the firm’s stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average cost of $21.34 per share, with a total value of $501,490.00. Following the completion of the transaction, the chief executive officer owned 29,533 shares in the company, valued at approximately $630,234.22. The trade was a 389.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.79% of the stock is currently owned by insiders.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.